

Transdermal Drug Delivery

Technologies, Companies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

July 2018

A Jain PharmaBiotech Report

A B O U T T H E A U T H O R

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 476 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Prof. Jain has edited "Drug Delivery Systems" (1st ed 2008, 2nd ed 2014, 3rd edn 2019, in preparation) and Drug Delivery to the Central Nervous System (2010), both published by Humana/Springer. His other recent books include "Handbook of Nanomedicine" (Springer/Humana 2008; Chinese ed, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer 2017), "Application of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Application of Biotechnology in Neurology" (Springer 2013), and "Application of Biotechnology in Oncology" (Springer 2014)

A B O U T T H I S R E P O R T

The original report on Transdermal Drug Delivery appeared as a section in the author's Drug Delivery Systems published by Decision Resources Inc in 1998. The second edition was published by Informa Pharmaceuticals after detaching Cancer Drug Delivery and Central Nervous System Drug Delivery as separate reports in 2000. In 2002, Transdermal Drug Delivery was also detached, expanded and updated to be issued as separate publications by Jain PharmaBiotech. The report was regularly updated since 2002, enlarged and rewritten for 2017 edition.

July 2018
Copyright © 2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	10
1. Basics of Transdermal Drug Delivery	12
Introduction	12
Historical landmarks in transdermal drug delivery	12
Anatomy and physiology of skin	13
Skin metabolomics and transcutaneous passage of drugs.....	13
Transcutaneous absorption	14
Transdermal versus other methods of drug delivery.....	14
Advantages of transdermal drug delivery	14
<i>First-Pass Effect.....</i>	<i>14</i>
Drawbacks of transdermal delivery.....	14
Factors that influence transdermal drug delivery	15
Rate of permeation across the skin	15
Properties of the skin	16
Properties of drugs.....	16
<i>The role of pH and pharmacokinetics</i>	<i>17</i>
<i>Intradermal disposition of drugs after topical application.....</i>	<i>17</i>
Role of nanobiotechnology in understanding basis of transdermal delivery	17
2. Transdermal Drug Delivery Technologies	20
Introduction	20
Local application formulations	21
Crystalline topical formulations	21
Microemulsions for transdermal drug delivery	21
Nanoemulsions for transdermal drug delivery	22
Transdermal gel technology	22
Biphase system.....	24
Penetration enhancers.....	24
Chemical enhancers	24
<i>Nitric oxide-based transdermal drug delivery.....</i>	<i>26</i>
Ionic liquids for transdermal delivery of drugs against bacterial biofilms on skin	27
Vesicular transdermal carriers	27
<i>Liposomes.....</i>	<i>27</i>
<i>Transfersomes.....</i>	<i>28</i>
<i>Ethosomes</i>	<i>28</i>
<i>Elastic vesicles for transdermal drug delivery</i>	<i>29</i>
<i>Nanovesicles for transdermal drug delivery</i>	<i>29</i>
Transdermal patches	30
Adhesives for transdermal patches.....	31
Commercial development of transdermal patches	32
Innovations in transdermal patches.....	32
<i>e-Patch™ controlled release micropump system.....</i>	<i>33</i>
<i>Patchless Transdermal Delivery System</i>	<i>33</i>
<i>Metered-dose transdermal system</i>	<i>34</i>
Polymers for transdermal drug delivery.....	34
Polymer membranes in transdermal patches	35
Film forming polymeric solutions.....	36
Crystal Reservoir System of Nitto Denko	36
Use of physical modalities to facilitate transdermal transport	37
Transdermal electrotransport	37
Electroporation	37
<i>Drug delivery by electroporation</i>	<i>38</i>
Cryoelectrophoresis.....	39
Iontophoresis	40
<i>Iontophoresis compared with electrophoresis</i>	<i>40</i>
<i>Application of iontophoresis for drug delivery</i>	<i>40</i>
<i>Patents in iontophoresis.....</i>	<i>42</i>
<i>Companies with technologies for drug delivery by iontophoresis</i>	<i>42</i>
Combination of electrophoresis and iontophoresis	43
<i>Dermaportation</i>	<i>43</i>
Radiofrequency-driven transdermal delivery	44
Microporation	44
Transcutaneous drug delivery by electropulsation	44
Companies involved in electroporation-based drug delivery	45
Electrode Scanning System	45
Use of electrostatic force in skin patch technology.....	46

Multiple Absorption Kinetic System.....	46
Transdermal drug delivery facilitated by heat	46
<i>Controlled, heat-aided drug delivery</i>	46
Ultrasound	47
Magnetophoresis.....	48
Use of lasers for transdermal drug delivery	49
<i>Laser-induced microporation</i>	49
<i>Transdermal drug delivery by laser-induced pressure waves</i>	49
<i>Transdermal drug delivery by laser-assisted changes in skin</i>	50
Transdermal delivery by gas under pressure	50
<i>Transdermal delivery with PowderJect gas gun</i>	50
<i>Microscission induced by gas</i>	51
Role of microelectronics in transdermal drug delivery	51
Microneedles and dermal microinjection technologies	52
Applications of microneedles	53
AdminPatch® microneedle array.....	54
Biodegradable microneedles.....	54
Ceramic microneedle arrays	55
Dissolvable microneedle patches.....	55
MicorCor	55
Microneedle arrays for drug delivery.....	56
Microneedle patch.....	57
MicroPyramid™ microneedles	57
Microstructured Transdermal Systems	58
Microneedle Array Patch technology	58
Microneedle transdermal chip	59
Microneedle applicator device.....	59
Nanoject™ microneedle technology	59
PatchPump.....	60
Polymer microneedles	60
Silk microneedles.....	61
Tattooing for drug delivery.....	61
ZP Patch microprojections technology.....	62
Companies developing microneedles for transdermal drug delivery	62
Needlefree injections	63
Glide SDI® solid dose injector	63
Jet injection	63
Mini-Ject needlefree delivery system	63
MicroJet for painless injections	64
Nanoliter-volume pulsed microjets	64
SUMAVEL™ DosePro™ needle-less injection	64
Skin ablation or abrasion for drug delivery	65
Nanotechnology-based transdermal drug delivery	65
Delivery of nanostructured drugs from transdermal patches	65
Effect of mechanical flexion on penetration of bucky balls through the skin	66
Nanobiotechnology for transdermal application	66
<i>Nanoparticles and nanoemulsions for skin disorders</i>	66
<i>Nanopatches</i>	67
<i>Inocyte™ epidermal drug delivery system</i>	67
<i>Ionic nanoparticle technology</i>	67
<i>SLN gel for treatment of skin disorders</i>	68
<i>Topical delivery of siRNA- nanoparticle conjugates</i>	68
<i>Transdermal nanoparticle preparations for systemic effect</i>	68
<i>Transferosomes for transdermal drug delivery</i>	69
<i>Transdermal administration of nanocarriers</i>	69
Nanotechnology-based transdermal vaccination and immunotherapy.....	70
Safety issues of applications of nanomaterial carriers on the skin.....	70
Comparison of transdermal drug delivery systems	70
Transdermal drug design	71
In vitro testing of transdermal drug delivery systems	71
<i>Commercially available skin models for transdermal drug testing</i>	72
<i>FDA guidelines for post-approval changes in semisolid topical drugs</i>	72
In vivo testing of drug delivery systems	73
Infrared spectroscopy for evaluation of transdermal drug delivery.....	73
Modeling of transport through the skin	73
Concluding remarks on transdermal drug delivery technologies	74
Future developments in transdermal drug delivery	74
3. Transdermal Therapeutics	76
Introduction	76
Drugs that can be administered transdermally	76

Approved transdermal products	76
Drugs in clinical trials	78
Skin disorders.....	79
Cutaneous leishmaniasis	79
Hair loss	79
Iontophoretic drug delivery for nail disorders.....	80
Psoriasis	80
<i>Nanoemulsions for paclitaxel delivery in psoriasis.....</i>	<i>80</i>
<i>Iontophoresis for treatment of psoriasis.....</i>	<i>80</i>
Cardiovascular disorders	81
Transdermal estrogen for prevention of atherosclerotic cardiovascular disease	81
Transdermal drug delivery for angina pectoris	81
Transdermal drug delivery for hypertension	82
<i>Transdermal clonidine</i>	<i>83</i>
<i>Transdermal delivery of β-blockers for hypertension.....</i>	<i>83</i>
<i>Transdermal delivery of calcium channel blockers for hypertension</i>	<i>84</i>
Transdermal drug delivery for congestive heart failure.....	84
Transdermal beta blockers	84
Transdermal anticoagulants	85
Respiratory diseases.....	85
Asthma.....	85
Chronic obstructive pulmonary disease	86
Neurological and psychiatric disorders	87
Parkinson's disease	87
<i>Transdermal drug delivery for Parkinson's disease</i>	<i>87</i>
<i>Transdermal levodopa delivery systems.....</i>	<i>87</i>
<i>Transdermal dopamine agonists for Parkinson's disease.....</i>	<i>88</i>
<i>Rotigotine for Parkinson disease</i>	<i>89</i>
<i>Rotigotine for restless legs syndrome</i>	<i>91</i>
<i>Transdermal administration of other drugs for Parkinson disease</i>	<i>91</i>
Depression.....	91
<i>Antidepressants.....</i>	<i>92</i>
<i>Selective serotonin-reuptake inhibitors</i>	<i>92</i>
<i>Transdermal fluoxetine.....</i>	<i>92</i>
<i>Monoamine oxidase inhibitors.....</i>	<i>93</i>
<i>Transdermal selegiline.....</i>	<i>93</i>
<i>Trazodone hydrochloride.....</i>	<i>94</i>
<i>Venlafaxine</i>	<i>94</i>
<i>Bupropion</i>	<i>94</i>
Bipolar disorder	95
<i>Transdermal lithium</i>	<i>95</i>
Schizophrenia.....	96
<i>Transdermal haloperidol</i>	<i>96</i>
<i>Transdermal risperidone for treatment of schizophrenia.....</i>	<i>96</i>
<i>Transdermal blonanserin for treatment of schizophrenia</i>	<i>96</i>
Restless legs syndrome	97
Alzheimer's disease	97
<i>Transdermal rivastigmine.....</i>	<i>97</i>
<i>Transdermal donepezil.....</i>	<i>98</i>
<i>Transdermal galantamine.....</i>	<i>98</i>
<i>Transdermal arecoline</i>	<i>99</i>
Transdermal nicotine for Tourette syndrome	99
Attention deficit hyperactivity disorder.....	99
<i>Transdermal methylphenidate</i>	<i>99</i>
Migraine	100
<i>Transdermal sumatriptan</i>	<i>100</i>
<i>Transdermal zolmitriptan</i>	<i>101</i>
<i>Transdermal dihydroergotamine</i>	<i>101</i>
Epilepsy.....	102
Tinnitus/Vertigo.....	102
Transdermal nitroglycerin for vasospasm due to subarachnoid hemorrhage.....	102
Musculoskeletal disorders.....	102
Osteoporosis	102
<i>Transdermal alendronate</i>	<i>103</i>
<i>Transdermal estrogen.....</i>	<i>103</i>
<i>Transdermal human parathyroid hormone.....</i>	<i>103</i>
Osteoarthritis	104
Transdermal therapy of diabetes	104
Insulin delivery in diabetes by transdermal patches.....	104
Microneedle patch for glucose-responsive insulin delivery	105
Patch monitoring system for insulin delivery.....	105

Sonic Applicator & Control Device for TDD of insulin	106
V-Go® disposable insulin delivery device	106
ViaDor System for TDD of insulin	106
Companies developing devices for transdermal insulin delivery	107
Transdermal therapy of oral antidiabetic agents.....	107
<i>Transdermal antidiabetic agents other than insulin</i>	108
Male disorders	108
Erectile dysfunction	108
<i>Topical and transdermal preparation for erectile dysfunction</i>	108
Hypogonadism in the male.....	109
<i>Topical testosterone</i>	109
Benign prostatic hypertrophy.....	111
<i>Tamsulosin TDS</i>	111
Women's health.....	111
Female sexual arousal disorder.....	111
Menopause.....	112
<i>Hormone replacement therapy for menopause</i>	112
<i>Effect of transdermal estradiol on bone density</i>	114
<i>Transdermal PTH for postmenopausal osteoporosis</i>	114
<i>Transdermal testosterone for low libido in postmenopausal women</i>	114
Breast disorders	115
Dysmenorrhea.....	115
Female infertility	115
Contraception	116
Female contraception	116
<i>Ortho Evra™</i>	116
<i>AG200-15</i>	117
<i>BAY86-5016</i>	117
<i>Desogestrel</i>	117
Male contraception.....	118
<i>Transdermal progestin plus testosterone</i>	118
Cancer	118
Delivery of the photosensitizer drug δ -amino levulinic acid.....	118
Intradermal delivery of cancer vaccines by adenoviral vectors	119
Nanoemulsion-based delivery of caffeine for skin cancer.....	119
Topical interferon α 2b for cervical cancer and precancerous lesions	119
Transcutaneous electroporation for delivery of anticancer drugs	120
Transdermal delivery of peptide cancer vaccines.....	120
Transdermal drug delivery for prostate cancer.....	120
<i>Transdermal nitroglycerine for prostate cancer</i>	120
<i>Transdermal estradiol gel for prostate cancer</i>	121
<i>Transdermal leuprolide acetate for prostate cancer</i>	121
Transdermal drug delivery for breast cancer.....	121
<i>Afimoxifene topical gel for breast cancer</i>	121
Pain	121
Relief of pain associated with minor medical procedures	121
Transdermal lidocaine relief of postherpetic neuralgia	122
<i>Lidoderm®</i>	122
<i>Lidopat®</i>	122
<i>ZTlido</i>	122
Transdermal capsaicin for relief of pain.....	122
Nonsteroidal antiinflammatory drugs	123
<i>Topical NSAIDs</i>	123
<i>Transdermal ketoprofen</i>	124
<i>Topical opioids</i>	125
Cancer pain.....	125
<i>Transdermal fentanyl</i>	125
<i>Transdermal nitroglycerine as an adjuvant to opioids</i>	126
<i>Transdermal buprenorphine</i>	126
Chronic pain of non-malignant origin	127
Transdermal local anesthetics.....	127
Postoperative pain	127
<i>Transdermal fentanyl for the management of postoperative pain</i>	127
<i>Fibromyalgia</i>	128
Nanotechnology-based approved transdermal analgesic preparations	128
Nausea and vomiting	128
Motion sickness	128
Postoperative vomiting	128
Chemotherapy-induced nausea and vomiting	129
Antiaging strategies	129
Smoking cessation.....	129

Transdermal nicotine replacement.....	129
Use of nicotine patch for smoking cessation in pregnancy	130
Other methods of nicotine replacement	131
Other treatments for smoking cessation.....	131
Miscellaneous uses of transdermal drug delivery.....	131
Allergic rhinitis.....	131
Chronic fatigue syndrome	132
Overactive bladder and urinary incontinence	132
<i>Transdermal oxybutynin</i>	<i>132</i>
Viral infections.....	133
<i>Transdermal nanoparticles for immune enhancement in HIV.....</i>	<i>133</i>
<i>Transdermal IQP-0410 for HIV/AIDS</i>	<i>134</i>
Wound healing and ulcers	134
Transdermal gene therapy.....	135
Transdermal delivery of plasmid DNA by electroporation	135
Transdermal antisense therapy	135
Transdermal vaccination.....	136
The skin as an immune organ.....	136
Technologies for transdermal vaccination.....	136
<i>Dissolvable microneedle array for vaccine delivery</i>	<i>136</i>
<i>Electroporation for administering DNA vaccines</i>	<i>137</i>
<i>Microneedles for transdermal delivery of vaccines</i>	<i>138</i>
<i>Needle-free delivery of vaccines.....</i>	<i>139</i>
<i>Transcutaneous immunotherapy using nanodispersions</i>	<i>140</i>
Applications of transdermal vaccination	141
<i>HIV/AIDS vaccination by topical application.....</i>	<i>141</i>
<i>Transdermal DNA influenza vaccine.....</i>	<i>141</i>
<i>Transdermal Aβ vaccination for Alzheimer's disease</i>	<i>142</i>
<i>Transdermal vaccination for traveller's diarrhoea</i>	<i>142</i>
Transdermal nutraceuticals	142
Complications of transdermal therapy	143
Adverse effects of drugs	143
Overdose effect	143
Skin complications	144
<i>MRI-induced skin burns from transdermal patches</i>	<i>144</i>
4. Markets for Transdermal Drug Delivery	146
Introduction	146
Global markets for drug delivery	146
Geographical distribution of transdermal drug delivery markets	147
Emerging transdermal drug delivery markets in Asia	147
Transdermal technology markets in therapeutic areas	147
Angina pectoris.....	148
Attention deficit hyperactivity disorder.....	148
Erectile dysfunction.....	149
Hypertension.....	149
Osteoporosis	149
Pain therapeutics	149
Parkinson's disease	149
Smoking cessation	150
Transdermal hormone replacement therapy for menopause	150
Transdermal testosterone replacement therapy for hypogonadism in the male	150
Transdermal contraceptive market	150
Markets according to transdermal technologies.....	151
Markets for microneedle-based transdermal drug delivery.....	151
Marketing strategies for transdermal drug delivery.....	151
Marketing advantages of transdermal drug delivery.....	152
Unmet needs in transdermal drug delivery	152
Regulatory aspects that affect transdermal drug delivery markets.....	153
Future prospects of transdermal drug delivery	154
Growth of new technologies used in transdermal drug delivery	154
Prospects of transdermal delivery for drugs coming off patents.....	154
Transdermal delivery of biologicals.....	155
Transdermal delivery of cosmetics	155
5. Companies involved in transdermal drug delivery	156
Profiles of companies.....	156
Top companies in transdermal drug delivery.....	156
Collaborations.....	284
6. References.....	288

Tables

Table 1-1: Historical landmarks in the development of transdermal drug delivery	12
Table 1-2: Transdermal vs oral and intravenous drug delivery	14
Table 1-3: Size ranges of molecules that can be delivered by transdermal route.....	17
Table 2-1: Technologies for transdermal drug delivery	20
Table 2-2: Chemical enhancers of skin penetration	25
Table 2-3: Drug-in-adhesive versus reservoir type of transdermal patch.....	30
Table 2-4: Companies with transdermal patches for drug delivery.....	32
Table 2-5: Companies with technologies for drug delivery by iontophoresis.....	42
Table 2-6: Companies involved in electroporation-based drug delivery	45
Table 2-7: Companies developing microneedles for transdermal drug delivery.....	62
Table 2-8: Comparison of transdermal drug delivery systems.....	71
Table 3-1: Approved transdermal products	76
Table 3-2: Transdermal drugs in clinical trials or approval process	78
Table 3-3: Companies developing devices for transdermal insulin delivery	107
Table 3-4: Selected transdermal systems GLP-1 antidiabetic agents.....	108
Table 4-1: Worldwide drug delivery market growth 2017 to 2027	146
Table 4-2: Transdermal drug delivery markets for geographical regions 2017 to 2027.....	147
Table 4-3: Markets for transdermal products for therapeutic areas 2017-2027	148
Table 4-4: Markets according to transdermal technologies 2017-2027.....	151
Table 4-5: Marketing strategies based on transdermal drug delivery technologies.....	151
Table 5-1: Top ten companies in transdermal drug delivery	156
Table 5-2: Collaborations in transdermal drug delivery	284

Figures

Figure 1-1: Basic structure of the skin.....	13
Figure 1-2: Events governing transcutaneous drug absorption	15
Figure 2-1: Basic structure and function of transdermal drug delivery systems.....	30
Figure 2-2: Transdermal system for delivery of liquid drugs	31
Figure 2-3: Crystal Reservoir System of Nitto Denko	36
Figure 2-4: A schematic view of electroporation.....	37
Figure 2-5: Depiction of breakdown of the stratum corneum during electroporation	39
Figure 2-6: A schematic drawing of Iontophoresis.....	40
Figure 2-7: SonoPrep ultrasonic skin permeation	48
Figure 2-8: A a schematic sketch of PowderJect gas gun.....	51
Figure 2-9: Drug delivery using different types of microneedles (MN).....	52
Figure 2-10: A schematic drawing of the microneedle patch	57
Figure 2-11: Preparation of solid-in-oil nanodispersion for transdermal application.....	66
Figure 3-1: Oral versus transdermal administration of a drug in Parkinson's disease	90
Figure 3-2: Control functions and user interface of insulin patch monitoring system	106
Figure 3-3: Transcutaneous immunotherapy using nanodispersions	140
Figure 4-1: Unmet needs in transdermal drug delivery	153